Avanzanite Bioscience Expands UK Operations, Appoints Sarah O’Connell as Country Manager to Strengthen Rare Disease Medicine Access
Avanzanite Bioscience B.V., a European pharmaceutical company specializing in rare diseases, has announced the expansion of its United Kingdom (UK) operations and the appointment of Sarah O’Connell as UK Country Manager. The appointment reinforces the company’s long-term commitment to the UK pharmaceutical market and strengthens its efforts to improve access to innovative medicines for eligible patients living with rare diseases.
The expansion represents another milestone in Avanzanite Bioscience’s strategy to establish an integrated pan-European commercial platform that helps pharmaceutical partners bring rare disease treatments to patients across diverse healthcare systems. By strengthening its local leadership and operational capabilities in the UK, the company aims to build closer relationships with the National Health Service (NHS), healthcare professionals, patient communities, and other stakeholders involved in the delivery of specialist medicines.
O’Connell brings more than 25 years of pharmaceutical industry experience, including senior strategic positions at Amicus Therapeutics and Chiesi. Her background encompasses rare disease commercialization, market access, and commercial leadership. During her tenure at Amicus Therapeutics, she led a small, agile team that achieved market leadership within the treatable patient population just eight months after a product launch.
Her appointment is expected to support Avanzanite’s efforts to strengthen its UK presence, develop local partnerships, and improve the execution of market access strategies for innovative rare disease medicines. The company views the UK as an essential component of its European growth ambitions and intends to continue investing in the capabilities needed to serve patients and pharmaceutical partners over the long term.
Adam Plich, co-founder and CEO of Avanzanite Bioscience, emphasized the strategic importance of the UK market and the company’s decision to strengthen its local presence.
“The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” Plich said.
He added that the company’s decision reflects its commitment to building a sustainable presence in the country at a time when some organizations across the life sciences sector are reassessing their UK investments and operations.
“At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare disease, market access and commercial leadership experience, we are strengthening the local capabilities and execution needed to ensure no patient in need is left behind.”
The appointment aligns with Avanzanite’s broader objective of connecting pharmaceutical innovation with patients who may face barriers to accessing specialist treatments, particularly in rare disease markets where patient populations are small and healthcare pathways can be complex.
Strengthening Avanzanite’s Long-Term Commitment to the UK
The UK expansion highlights Avanzanite Bioscience’s intention to maintain and develop a substantial presence in one of Europe’s important pharmaceutical and healthcare markets.
The UK combines established biomedical research capabilities, specialist clinical expertise, and a national healthcare system that provides a framework for evaluating and delivering innovative treatments. However, bringing medicines for rare diseases to eligible patients can require extensive coordination among pharmaceutical companies, healthcare providers, reimbursement stakeholders, and patient organizations.
Rare diseases frequently affect relatively small patient populations, and the number of diagnosed individuals eligible for a particular treatment may be limited. These characteristics can create challenges for companies seeking to establish sustainable commercial operations while ensuring that patients can access therapies within appropriate healthcare pathways.
Market access is particularly important in this environment. Pharmaceutical companies must navigate country-specific regulatory requirements, health technology assessments, reimbursement decisions, procurement processes, and local clinical practices. Even when an innovative treatment is available, additional work may be needed to ensure that eligible patients and their treating clinicians can access it.
Avanzanite’s strategy is designed to address these challenges through a combination of local expertise and integrated European capabilities. By strengthening its UK leadership, the company aims to develop a more effective local operating model that can respond to the needs of healthcare stakeholders while supporting its pharmaceutical partners.
The appointment of a dedicated UK Country Manager is intended to help coordinate these activities and strengthen the company’s engagement with the NHS, clinicians, and patient communities.
O’Connell’s experience in rare disease commercialization and market access is particularly relevant to this approach. Her leadership is expected to help Avanzanite develop an agile UK organization capable of identifying market opportunities, establishing partnerships, and supporting the introduction of innovative medicines through the country’s healthcare system.
The company has positioned the expansion as a long-term investment rather than a short-term commercial initiative. This approach reflects its ambition to establish a durable presence in the UK and make the market an integral part of its wider European operations.
Sarah O’Connell Brings More Than 25 Years of Pharmaceutical Experience
O’Connell joins Avanzanite Bioscience with more than 25 years of experience in the pharmaceutical industry, including senior strategic roles at Amicus Therapeutics and Chiesi.
Her professional background includes experience in rare disease markets, commercial strategy, and market access. These areas are closely connected in specialist pharmaceutical commercialization, where companies must coordinate scientific evidence, healthcare stakeholder engagement, and commercial execution to support patient access.
At Amicus Therapeutics, O’Connell led a small, agile team that achieved market leadership within the treatable patient population eight months after launch. The achievement illustrates her experience in translating commercial strategy into measurable market performance in a specialized treatment setting.
Rare disease commercialization often requires a focused approach because the eligible patient population may be geographically dispersed, and treatment decisions may be concentrated among specialist physicians and designated clinical centers.
Companies operating in these markets must develop a clear understanding of patient identification, referral pathways, specialist treatment practices, and the requirements that determine eligibility for therapy. Effective engagement with healthcare professionals and patient communities can also be important to ensuring that available treatments reach the people for whom they are intended.
O’Connell’s previous experience is expected to support Avanzanite’s efforts to navigate these considerations in the UK. Her responsibilities as Country Manager will center on strengthening the company’s local organization and helping translate its broader European strategy into market-specific execution.
Her appointment also supports the company’s emphasis on combining local knowledge with the resources of a larger international platform. While a pan-European organization can provide scale and shared capabilities, successful commercialization often depends on understanding the particular healthcare environment in each country.
For Avanzanite, this means maintaining the ability to work closely with UK stakeholders while coordinating activities with teams across its broader European network.
Connecting Scientific Innovation With Patient Impact
Commenting on her appointment, O’Connell emphasized that developing innovative medicines is only the first step in improving outcomes for people living with rare diseases.
“Scientific innovation is only the beginning; patient impact is the goal,” O’Connell said.
She highlighted the UK’s combination of scientific expertise and healthcare infrastructure, while noting that additional collaboration and effective execution are necessary to translate innovation into meaningful patient benefits.
“The UK combines exceptional scientific expertise with a health system capable of delivering innovation at scale, but turning that potential into patient impact requires partnership, innovative thinking, and disciplined Champions League-level execution. I am excited to build an agile UK organisation and work closely with the NHS, clinicians, and patient communities to help innovative rare disease medicines reach the people who need them.”
Her comments reflect a central challenge in rare disease medicine development: scientific progress does not automatically guarantee that a treatment will reach all eligible patients.
Following the development and authorization of a medicine, companies may still need to navigate reimbursement requirements, healthcare system processes, specialist prescribing practices, and other factors that influence availability. Patient identification and referral can also be important, particularly when diseases are uncommon and symptoms may overlap with those of more prevalent conditions.
Close collaboration among pharmaceutical companies, healthcare professionals, health systems, and patient organizations can help identify barriers and improve understanding of the pathways through which patients receive treatment.
Avanzanite’s UK strategy is intended to strengthen these relationships and support the local execution required to bring specialist medicines to eligible patients.
The company’s approach also emphasizes the importance of agility. An organization that can adapt its activities to local healthcare requirements may be better positioned to respond to different access conditions, particularly in rare disease markets where the needs of patients and specialist centers can vary substantially.
Building on an Existing UK Team
The expansion builds on Avanzanite Bioscience’s existing UK organization, which comprises 13 UK-based employees, including three executives.
The appointment of O’Connell adds dedicated country-level leadership to this existing structure and represents the latest step in the company’s development of an integrated pan-European platform.
Rather than operating solely through a centralized European model, Avanzanite combines local country teams with shared capabilities designed to support its pharmaceutical partners across multiple markets. This structure is intended to help the company respond to differences in national healthcare systems, market access requirements, and commercial conditions.
The company describes its broader workforce as a “Champions League” team, reflecting its emphasis on specialist expertise, coordinated execution, and performance across its European operations.
With O’Connell’s appointment, this organization comprises more than 100 employees operating across 32 countries, including the European Economic Area (EEA), Switzerland, and the UK.
The network provides Avanzanite with a presence across a wide range of European markets, allowing it to support pharmaceutical partners seeking to reach eligible patient populations beyond the largest national markets.
For companies developing medicines for rare diseases, this geographic reach can be particularly relevant. Although a treatment may address a serious unmet medical need, the number of eligible patients in any individual country may be relatively small. Reaching patients across multiple markets can therefore require an operating model that combines country-specific expertise with coordinated regional capabilities.
Avanzanite’s integrated structure is intended to support that objective by bringing together local teams and shared resources. Country teams can work within their respective healthcare environments, while the broader platform supports coordination across markets.
The UK expansion strengthens this model by reinforcing the company’s ability to engage with one of Europe’s major healthcare systems and maintain closer relationships with local stakeholders.
Supporting Pharmaceutical Partners Across Diverse Markets
Avanzanite Bioscience’s business model focuses on helping pharmaceutical partners improve access to innovative medicines for rare diseases across Europe.
The company’s country teams and integrated capabilities are designed to support market entry and commercialization in markets with different levels of complexity. These include countries where access pathways may be challenging, as well as smaller or underserved markets that can be difficult for pharmaceutical companies to serve through conventional commercial structures.
Market access conditions can differ considerably between European countries. Healthcare financing arrangements, reimbursement processes, procurement requirements, clinical guidelines, and the organization of specialist care can all influence how a medicine reaches patients.
For pharmaceutical companies operating across multiple jurisdictions, managing these differences can require significant local expertise and coordination. The resources required to establish a commercial presence in every country may also be difficult to justify when the eligible patient population is small.
Avanzanite’s pan-European platform is designed to help address these challenges by providing local capabilities within a broader integrated organization.
Through its country teams, the company aims to help partners navigate individual markets and support the commercialization of specialist medicines. The model may be particularly relevant for rare disease therapies, where the number of eligible patients can be limited but the medical need may be substantial.
The expansion of the UK organization forms part of this wider strategy. By investing in local leadership and maintaining an established team, Avanzanite aims to strengthen its ability to work with UK healthcare stakeholders and support access to appropriate treatments.
The company has not announced a specific new medicine launch or additional product authorization as part of this appointment. Instead, the expansion focuses on strengthening the organizational capabilities required to support its existing and future commercial activities.
Advancing a Pan-European Rare Disease Platform
The appointment of O’Connell comes as Avanzanite continues to develop an integrated platform intended to convert the complexity of European pharmaceutical markets into commercial opportunities for its partners.
Its operations across 32 countries provide a foundation for supporting rare disease medicine commercialization across the EEA, Switzerland, and the UK. The combination of local country teams and integrated capabilities is designed to help partners navigate different healthcare systems while maintaining a coordinated approach to market development.
The UK remains a significant component of this strategy because of its scientific expertise, specialist clinical infrastructure, and national healthcare system. Strengthening the company’s presence in the country may help improve coordination with healthcare stakeholders and support the execution of market-specific access strategies.
O’Connell’s background in rare disease commercialization, market access, and strategic leadership is expected to contribute to these objectives. Her experience building a successful commercial team at Amicus Therapeutics may also be relevant as Avanzanite continues to develop its local organization.
The company’s longer-term ambition is to ensure that pharmaceutical innovation can translate into access for eligible patients across markets of different sizes and levels of complexity.
Achieving this objective will require continued collaboration with healthcare professionals, health systems, patient communities, and pharmaceutical partners, alongside an understanding of the requirements governing access to specialist medicines.
Avanzanite Bioscience’s expansion in the UK and the appointment of Sarah O’Connell as UK Country Manager represent important steps in the company’s efforts to strengthen its European rare disease operations.
With more than 25 years of pharmaceutical industry experience, including senior positions at Amicus Therapeutics and Chiesi, O’Connell brings expertise in commercial leadership, market access, and rare disease commercialization. Her appointment will support the company’s plans to strengthen local capabilities, build partnerships with the NHS and clinical stakeholders, and help innovative medicines reach eligible patients.
The expansion builds on an existing UK team of 13 employees and forms part of Avanzanite’s broader pan-European organization, which now comprises more than 100 employees across 32 countries.
By combining local market knowledge with integrated European capabilities, Avanzanite aims to support pharmaceutical partners in navigating complex healthcare environments, including smaller and underserved markets where access to specialist treatments can present particular challenges.
The company’s continued investment in the UK underscores its commitment to developing a long-term presence in the country and advancing its broader ambition of becoming a leading European rare disease pharmaceutical company. Through stronger local leadership and closer collaboration with healthcare stakeholders, Avanzanite aims to help bridge the gap between scientific innovation and access to treatment for people living with rare diseases.
About Avanzanite Bioscience
Avanzanite is a next-generation pharmaceutical company purpose-built to unlock the full potential of rare disease medicines across Europe. Founded in 2022 and headquartered in Amsterdam, the Netherlands, Avanzanite was created around a belief that scientific innovation creates patient impact only when medicines reach those who can benefit from them.
Through tailored partnerships, biopharma innovators entrust Avanzanite with the European future of their medicines. Avanzanite combines pan-European expertise, bold commercial and access strategy, together with high-performance execution, to transform Europe’s complexity into opportunity, ensuring no patient is left behind and creating lasting long-term value for partners.